Andrews C O, Gora M L
College of Pharmacy, University of Cincinnati, OH.
Ann Pharmacother. 1994 Jul-Aug;28(7-8):894-903. doi: 10.1177/106002809402800715.
To review the pathophysiology and management of pleural effusions, including available agents for pleural sclerosis.
A MEDLINE search (1966 to present) was performed that included clinical studies in the English language involving the pathophysiology and management of pleural effusions; references used in those articles were screened for additional published information.
All clinical trials were considered for potential inclusion in the review.
Pleural effusion is an accumulation of fluid in the pleural space that results when homeostatic forces that control the flow into and out of the area are disrupted. The management of transudative pleural effusions is primarily directed at treatment of the underlying disease. There are several treatment options for pleural effusions, including chemical pleurodesis. Many of the trials that examine the use of talc, bleomycin, and doxycycline have poorly described study designs and end points, with inconsistent evaluation of patients. Each agent is considered to be generally effective and safe, with fever and pain as the most frequently reported adverse effects. The use of talc requires sterilization, and many clinicians use general anesthesia with instillation, which increases the risk associated with the procedure. Bleomycin is generally safe; however, it should not be used in doses exceeding 40 mg/m2. Only uncontrolled trials support the use of doxycycline; however, it provides an effective, safe, and relatively inexpensive alternative.
Pleural effusions are defined as an accumulation of fluid in the pleural space. Treatment is generally palliative. Intrapleural administration of talc, bleomycin, and doxycycline are effective sclerosing agents for treatment of recurrent, symptomatic pleural effusions. Although the most cost-effective agent has not been determined, doxycycline is an inexpensive alternative to bleomycin, and may have fewer adverse effects than talc.
综述胸腔积液的病理生理学及治疗方法,包括现有的胸膜固定术用药。
进行了一项MEDLINE检索(1966年至今),纳入了涉及胸腔积液病理生理学及治疗方法的英文临床研究;对这些文章中引用的参考文献进行筛选以获取更多已发表信息。
所有临床试验均被考虑纳入本综述。
胸腔积液是胸膜腔内液体的积聚,是由于控制该区域液体流入和流出的稳态力量被破坏所致。漏出性胸腔积液的治疗主要针对基础疾病。胸腔积液有多种治疗选择,包括化学性胸膜固定术。许多研究滑石粉、博来霉素和强力霉素使用情况的试验,其研究设计和终点描述不佳,对患者的评估也不一致。每种药物一般都被认为有效且安全,发热和疼痛是最常报告的不良反应。滑石粉的使用需要灭菌,许多临床医生在注入时使用全身麻醉,这增加了该操作的相关风险。博来霉素一般安全;然而,其使用剂量不应超过40mg/m²。仅有非对照试验支持强力霉素的使用;然而,它提供了一种有效、安全且相对便宜的选择。
胸腔积液被定义为胸膜腔内液体的积聚。治疗通常是姑息性的。胸腔内注入滑石粉、博来霉素和强力霉素是治疗复发性、有症状胸腔积液的有效硬化剂。虽然尚未确定最具成本效益的药物,但强力霉素是博来霉素的便宜替代品,且可能比滑石粉的不良反应更少。